Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Patheon | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Patheon

Doug Mendenhall, Ph.D. has been named interim head of Patheon's Pharmaceutical Development Services Unit and will also serve as interim chief scientific officer.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Doug Mendenhall, Ph.D. has been named interim head of Patheon’s Pharmaceutical Development Services Unit and will also serve as interim chief scientific officer. Dr. Mendenhall is working under contract until a permanent president is named, but will be retained as an advisor to the company on an as-needed basis.

Dr. Mendenhall is a 35-year veteran in the pharmaceutical industry, having held executive positions at Abbott, GlaxoSmithKline and most recently, Merck. He has spent his career leading pharmaceutical and preclinical development teams with the development and commercialization of several blockbuster drugs.

“Doug brings a wealth of experience, maturity and strategic thinking to Patheon,” said Wes Wheeler, chief executive officer and president. “With Doug on our Executive Committee, both leading the PDS unit and advising us on strategy, we will enable further strategic growth of our development services offering to clients. We look forward to Doug’s leadership, as we continue our search for a permanent President.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters